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Introduction
Epidemiological evidence confirms an association be-
tween diabetes and increased prevalence of periphe-
ral arterial disease (PAD). Individuals with diabetes 
have a two- to fourfold increase in the rates of PAD.1,2 
Generally, they also have femoral bruits and absent 
pedal pulses,3 and rates of abnormal ankle-brachial 
indices ranging from 11.9-16%.4,5 The duration and se-
verity of diabetes correlates with the incidence and 
extent of PAD.6
Diabetes changes the nature of PAD. Generally, 
patients with diabetes have more infrapopliteal arterial 
occlusive disease and vascular calcification than 
nondiabetic cohorts.6 The Hoorn study7 examined 
the rates of PAD in groups ranging from patients with 
normal glucose tolerance, to those with diabetes 
requiring multiple medications. The 7% prevalence 
of abnormal ankle-brachial indices in individuals with 
normal glucose tolerance increased to 20.9% in those 
requiring multiple hypoglycaemic medications.
Usually, patients with diabetes develop the symptoma-
tic forms of PAD, intermittent claudication and ampu-
tation.8 In the Framingham cohort,9 the presence of 
diabetes increased the risk of claudication 3.5-fold in 
men and 8.6-fold in women. Worse, diabetes causes 
most nontraumatic lower extremity amputations in the 
USA.10 The relative risk of lower extremity amputation in 
patients with diabetes was 12.7 [95% confidence inter-
val (CI): 10.9-14.9] compared with that of nondiabetic 
patients in the Medicare population, and as high as 
23.5 (95% CI: 19.3-29.1) for persons with diabetes aged 
65-74 years.10
The protein beta-2 microglobulin (β2 microglobulin) is 
an 11.7-kDa nonglycosylated polypeptide comprising 
99 amino acids. It is one of the major histocompatibility 
complex class molecules on the cell surface of all 
nucleated cells. It interacts with and stabilises the 
tertiary structure of the major histocompatibility 
complex class I alpha-chain.11 This protein is present 
on almost all cells of the body. (Red blood cells are a 
notable exception.)12
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Abstract
Background: Peripheral arterial disease (PAD) is common in patients with type 2 diabetes mellitus. Its definitive 
diagnosis requires ultrasound or angiography. Beta-2 microglobulin (β2 microglobulin) has been proposed as a 
diagnostic marker for PAD. The objective of the study was to evaluate the diagnostic value of β2 microglobulin for 
PAD in patients with diabetes and varying renal function.
Design: This was a cross-sectional study. 
Setting: An academic centre (University of Pretoria and Steve Biko Academic Hospital Diabetes Clinic).
Subjects: One hundred and eight convenience-sampled patients.
Outcome measures: Patients completed a questionnaire and had toe and arm blood pressure (toe-arm index), as 
well as serum β2 microglobulin and creatinine, measured.
Results: Beta-2 microglobulin did not differ (p-value = 0.34) between those subjects with PAD (n = 43) and those 
without PAD (n = 65). In a linear regression model, the interaction term between estimated glomerular filtration rate 
categories and the inverse of β2 microglobulin was highly significant (p-value = 0.001).
Conclusion: Although the sample size was small, β2 microglobulin did not distinguish between subjects with and 
without PAD. Renal function and its effects on the association between β2 microglobulin and PAD need further 
study.
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In a study using proteomic profiling, β2 microglobulin 
was identified as a biomarker for PAD.13 After 
identification, β2 microglobulin was assessed in a 
validation study in a population at risk of acquiring 
PAD. Serum β2 microglobulin was higher in patients 
with PAD undergoing coronary angiography (n = 237). 
Also, the combination of β2 microglobulin and high-
sensitivity C-reactive protein (CRP) levels correlated 
with PAD diagnosis, independent of other vascular risk 
factors and glomerular filtration rate (GFR) by stepwise 
regression analysis. This was consistent with the earlier 
observation in the smaller confirmation study.13
Increasing age and diagnosis of diabetes mellitus were 
the other independent correlates of PAD diagnosis. 
The odds ratio for the diagnosis of PAD for elevated 
β2 microglobulin was 7.2 (95% CI: 1.6-31.3, p-value = 
0.009). The odds ratio was 1.3 (95% CI: 1-1.7, p-value = 
0.026) for high-sensitivity CRP.13 Because of its probable 
role in immunity and inflammation, the association of 
β2 microglobulin with PAD or with alterations in vascular 
structure,14 could relate to vascular inflammation.15
The abovementioned study demonstrated the ability of 
β2 microglobulin and CRP to predict PAD, independent 
of diabetes and GFR. However, no details were given 
on the prevalence of diabetes or the range of GFR. The 
results were also reported as standardised coefficients 
and not as measures of diagnostic accuracy.
It has been known for many decades that β2 
microglobulin increases with diminished renal function.16 
The normal synthesis rate of β2 microglobulin is 2-4 mg/
kg/day and the normal plasma level is 1-4 mg/l, which 
varies inversely with GFR. Usually, it is filtered through 
the renal glomeruli. Part of it is absorbed and catalysed 
by the renal tubular cells, while the nonabsorbed part is 
excreted in the urine.17 We investigated the diagnostic 




The setting of this cross-sectional study was the Diabetes 
Clinic at the Steve Biko Academic Hospital in Pretoria. 
This is a tertiary diabetes clinic in a public (state) 
hospital. The University of Pretoria Ethics Committee 
approved the study (231/2008).
Subject selection
Included was a convenience sample of subjects who 
were 50 years of age and older, with at least one first 
toe.
Research procedures
Consecutive patients who met the inclusion criteria 
were asked to participate. After agreeing and giving 
their signed informed consent, patients provided a 
urine sample and a venous blood sample. The blood 
samples were centrifuged. The serum and urine 
samples were snap frozen and stored at -700C. 
Patients completed a demographic and clinical 
questionnaire, which included the variables from the 
Rose questionnaire.18
In our vascular laboratory, after five minutes of supine 
rest, the brachial blood pressure was taken by a single 
investigator using a Baumanometer with a large cuff, 
,if the mid-arm circumference was larger than 35 cm, 
and a stethoscope. This was carried out twice. If there 
was a difference in the systolic blood pressure (SBP) of 
more than 6 mmHg, a third and decisive measurement 
was taken. The average of the two closest SBP 
measurements was used to calculate the toe brachial 
index (TBI). Blood pressure (in both the toes and the 
arm) was taken with a strict two-minute interval. 
Lastly, toe blood pressure was measured using a 
photoplethysmograph (DE Hokanson, MD6RP device). 
Before a measurement was taken, the foot temperature 
was measured using an infrared skin thermometer 
(Microlife™ Fr1DZ1). The temperature of the foot had to 
be at least 25ºC, otherwise the feet were warmed up for 
two minutes and then the temperature was measured 
again. A photo sensor was attached to the distal part of 
the pulp space. A miniature pneumatic blood pressure 
cuff was placed at the base of the toe, encircling 
the distal phalanx. After this, the toe blood pressure 
was taken. This was always carried out by the same 
two researchers, one operating the Baumanometer, 
and the other, the photoplethysmograph. Only SBP 
was measured. A mean systolic toe pressure was 
calculated by averaging the values obtained from the 
left and right toes. In the event of a difference of more 
than 6 mmHg, a third measurement was taken. In the 
absence of either the right or left hallux, two values 
were obtained in the remaining hallux and averaged, 
taking the two values that were closest to each other. 
To calculate the TBI, the mean of two brachial SBP 
readings was used. The toe SBP was divided by the 
systolic brachial blood pressure. The TBI was calculated 
per toe. 
A TBI of ≤ 0.75 in either foot was used to define PAD.19,20
To evaluate the TBI as a continuous measurement, the 
TBI of the left and right foot was averaged. (A single 
measurement was used in the case of any absent foot.)
Laboratory measurements
β2 microglobulin was assayed by nephelometry 
with Siemens N Latex B2 Microglobulin/OQWU15 
reagent using Siemens BN Prospec Nephelometer 
(Siemens Healthcare Diagnostics, Newark, USA), at 
the Department of Immunology, Tshwane Academic 
Division, National Health Laboratory Service. Serum 
and urine creatinine (non-isotype dilution mass 
spectrometry traceable) was measured at the National 
Health Laboratory Service Laboratory using the Jaffe 
method on the Synchron LX system. 
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Data analysis
The aim of the study was to determine whether β2 
microglobulin could distinguish between patients with 
and without PAD, and to investigate the association 
between β2 microglobulin and the TBI, taking into 
account the renal function of the patients.
Groups were compared with t-tests/Mann-Whitney 
tests and chi-square tests. The association between 
the TBI and renal function [estimated GFR (eGFR)] was 
investigated with linear regression. We transformed β2 
microglobulin to the inverse of β2 microglobulin (best 
approximation to normal). To determine the effect of 
renal function, we dichotomised the eGFR at 60 ml/
minute/m2. The regression analysis used the TBI of the 
left and right foot of the same patient if available, but 
corrected for clustering within the same patient. Stata® 
1221 was used for all analyses. A p-value < 0.05 was 
regarded as statistically significant.
Results
One hundred and seventeen patients were seen, of 
whom 108 had complete data for analysis. Of these, 
47% were men, 42% were black, 12% were current 
smokers, 30% were ex-smokers (stopped > 1 year ago), 
93% had hypertension, 17% had a history of myocardial 
infarction and 81% were statin users.
In Table I, patients with and without PAD are compared. 
The only variable that distinguishes the two groups 
is smoking (p-value = 0.08). Beta-2 microglobulin 
was higher in the PAD group, but also had a higher 
standard deviation. Possibly, this partly explains why 
the difference was not significant. The sample size was 
not large enough to stratify on estimated glomerular 
function. The Spearman rank correlation coefficient 
between β2 microglobulin and serum creatinine was 
0.41 (p-value < 0.0001).
The National Kidney Disease Education Program22 
recommends that laboratories report eGFR values of 
60 ml/minute/1.73 m2 (1 ml/second/1.73 m2) or greater 
simply as ≥ 60 ml/minute/1.73 m2. Thus, patients were 
categorised into those below 60 ml/minute/1.73 m2, 
and those above.
In Figure 1, there is a negative linear relationship 
between inverse β2 microglobulin and TBI. As β2 
microglobulin increases, TBI decreases, and vice versa, 
or inverse β2 microglobulin. However, this relationship 
is not true for the subjects with an eGFR ≥ 60 ml/
minute/1.73 m2.
In Table II, the regression coefficients for eGFR 
category (≥ 60 vs. < 60), inverse β2 microglobulin, 
and the interaction term (eGFR category x inverse β2 
microglobulin) are given. The interaction term is highly 
statistically significant, as can be deduced by the 
regression lines that are not parallel in Figure 1. Sex and 
age did not relate to PAD or β2 microglobulin, and so 
were not included in the models (data not shown).
Discussion
In this relatively small sample of 108 patients with dia-
betes, β2 microglobulin did not significantly distinguish 
between those patients with and those without PAD.
Patients with PAD had a greater variation in β2 
microglobulin levels, as depicted by the standard 
deviation, than those without PAD.
If the results are evaluated graphically using a 
regression interaction term, the relationship between β 
microglobulin and TBI appears to be modified by the 
level of eGFR (the association of β2 microglobulin with 
TBI is different at different levels of eGFR).








Male 29 (44.6%) 22 (51.2%) 0.64
Female 36 (55.4%) 21 (48.8%)
Diabetes mellitus type 
Type 1 9 (14.8%) 4 (9.8%)  
Type 2 52 (85.2%) 37 (90.2%)
Co-morbidities
Amputation 3 (5.0%) 4 (9.8%) 0.44
Hypertension 54 (88.5%) 39 (97.5%) 0.14
Revascularisation 9 (15.0%) 7 (17.1%) 0.99
Myocardial infarction 10 (16.7%) 7 (17.1%) 0.83
Intermittent claudication 8 (12.3%) 9 (20.9%) 0.23 
Smokers
No 41 (67.2%) 18 (45.0%) 0.08
Yes 5 (8.2%) 7 (17.5%)  
Ex 15 (24.6%) 15 (37.5%)
Race 0.41
White 26 (40.0%) 22 (51.2%)
Black 27 (41.5%) 18 (41.9%)
Coloured 5 (7.7%) 1 (2.3%)  
Indian 7 (10.8%) 2 (4.7%)  
Other
Cholesterol (mmol/l) 4.65 (1.29) 4.67  (1.30) 0.96




HDL (mmol/l) 1.02 (0.31) 1.01 (0.32) 0.93
LDL (mmol/l) 2.79 (1.18) 2.68  (0.92) 0.62
Creatinine (µmol/l)* 91, 77, 102 90.5, 80.3, 112.3 0.50
TBI right 0.95 (0.11) 0.70 (0.17) < 0.001
TBI left 0.93 (0.12) 0.64 (0.13) < 0.001
β2 microglobulin (mg/l)
* 2.0, 1.6, 2.5 2, 1.7, 2.8 0.35





* median and interquartile range
eGFR: estimated glomerular filtration rate, HDL: high-density lipoprotein, LDL: low-
density lipoprotein, PAD: peripheral arterial disease, TBI: toe brachial index
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The results do not support the findings of Wilson et 
al.13 However, our findings were contrary to what we 
expected. We expected that as the eGFR decreased, 
higher β2 microglobulin levels would not correlate with 
lower TBI levels. We observed the relationship being 
reversed when eGFR was ≥ 60 ml/minute per 1.73 m2.
Unfortunately, at the time that the study was carried out, 
our laboratory had not yet standardised the creatinine 
measurements (traceable to isotope dilution mass 
spectrometry). This would have allowed us to calculate 
eGFR according to the Chronic Kidney Disease-
Epidemiology Collaboration (CKD-EPI) method, which 
gives better estimates, especially when the GFR is 
> 60 ml/minute per 1.73 m2.23
Table I and Figure 1 show that the variation in β2 
microglobulin was greater in both the groups with PAD 
and the group with eGFR ≥ 60 ml/minute per 1.73 m2. 
This could explain why the same relationship was not 
observed across the categories of PAD and eGFR.
Another possible explanation for the discrepancy could 
be that the bouts of ischaemia that were postulated to 
cause the release of β2 microglobulin are dependent 
on the stage of chronic kidney disease, as the stage 
of the disease possibly correlates with the degree and 
manifestations of atherosclerosis.
Our study was limited because of its cross-sectional 
nature and its small sample size. However, in clinical 
practice, a marker should be able to clearly distinguish 
between diseased from nondiseased persons in 100 
patients, otherwise its clinical usefulness is doubtful.
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eGFR ≥ 60eGFR < 60Estimated glomerular filtration rate category
eGFR: estimated glomerular filtration rate, TBI: Toe brachial index
Figure I: The relationship between toe brachial index and inverse 
β2 microglobulin  by estimated glomerular filtration rate category
Table II: Toe brachial index regression coefficients adjusted for clustering of individuals
Change in TBI 
(coefficient)
Standard error 95% CI  
(lower limit)
95% CI  
(upper limit)
p-value
eGFR category 0 .33 0.11 0.12 0.55 0.003
Inverse β2 microglobulin 0.41 0.11 0.20 0.62 < 0.001
Interaction term - 0.62 0.19 - 0.99 -0.25 0.001
Constant 0.62 0.06 0.50 0.75 < 0.001
CI: confidence interval, eGRF: estimated glomerular filtration rate, TBI: toe brachial index
